Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study
Objectives Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB and HIV management remain scarce. Methods In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant (MDR) TB and use of antiretroviral th...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
W.B. Saunders Ltd
2018
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 28379caa a22020897a 4500 | ||
|---|---|---|---|
| 001 | PAPER-25385 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205725.0 | ||
| 008 | 190410s2018 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-85032918910 | |
| 024 | 7 | |2 cas |a aminosalicylic acid, 133-10-8, 133-15-3, 28088-64-4, 51540-64-8, 65-49-6, 80702-32-5, 133-09-5; cycloserine, 339-72-0, 68-39-3, 68-41-7; ethambutol, 10054-05-4, 1070-11-7, 3577-94-4, 74-55-5; ethionamide, 536-33-4; isoniazid, 54-85-3, 62229-51-0, 65979-32-0; protionamide, 14222-60-7; pyrazinamide, 98-96-4; rifampicin, 13292-46-1; streptomycin, 57-92-1; terizidone, 25683-71-0 | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a JINFD | ||
| 100 | 1 | |a Efsen, A.M.W. | |
| 245 | 1 | 0 | |a Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study |
| 260 | |b W.B. Saunders Ltd |c 2018 | ||
| 270 | 1 | 0 | |m Efsen, A.M.W.; Rigshospitalet, University of Copenhagen, CHIP, Department of Infectious Diseases, Section 2100 (CHIP), Blegdamsvej 9, Denmark; email: anne.marie.werlinrud.efsen@regionh.dk |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a World Health Organization, Global Tuberculosis Report (2015), http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf, Available from: (Accessed 1 October 2017); Zumla, A., Chakaya, J., Centis, R., D'Ambrosio, L., Mwaba, P., Bates, M., Tuberculosis treatment and management–an update on treatment regimens, trials, new drugs, and adjunct therapies (2015) Lancet Respir Med, 3 (3), pp. 220-234 | ||
| 504 | |a Daley, C.L., Caminero, J.A., Management of multidrug resistant tuberculosis (2013) Semin Respir Crit Care Med, 34 (1), pp. 44-59 | ||
| 504 | |a Casali, N., Nikolayevskyy, V., Balabanova, Y., Harris, S.R., Ignatyeva, O., Kontsevaya, I., Evolution and transmission of drug-resistant tuberculosis in a Russian population (2014) Nat Genet, 46 (3), pp. 279-286 | ||
| 504 | |a Acosta, C.D., Dadu, A., Ramsay, A., Dara, M., Drug-resistant tuberculosis in Eastern Europe: challenges and ways forward (2014) Public Health Action, 4, pp. S3-12 | ||
| 504 | |a Balabanova, Y., Ignatyeva, O., Fiebig, L., Riekstina, V., Danilovits, M., Jaama, K., Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference? (2016) Thorax, 71, pp. 854-861 | ||
| 504 | |a Skrahina, A., Hurevich, H., Zalutskaya, A., Sahalchyk, E., Astrauko, A., Hoffner, S., Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors (2013) Bull World Health Organ, 91 (1), pp. 36-45 | ||
| 504 | |a Skrahina, A., Hurevich, H., Zalutskaya, A., Sahalchyk, E., Astrauko, A., van Gemert, W., Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk (2012) Eur Respir J, 39 (6), pp. 1425-1431 | ||
| 504 | |a UNAIDS, AIDS by the numbers (2015), http://www.unaids.org/sites/default/files/media_asset/AIDS_by_the_numbers_2015_en.pdf, WORLD AIDS DAY; Available from: (Accessed 1 October 2017); Yablonskii, P.K., Vizel, A.A., Galkin, V.B., Shulgina, M.V., Tuberculosis in Russia. Its history and its status today (2015) Am J Respir Crit Care Med, 191 (4), pp. 372-376 | ||
| 504 | |a DeHovitz, J., Uuskula, A., El-Bassel, N., The HIV epidemic in Eastern Europe and Central Asia (2014) Curr HIV/AIDS Rep, 11 (2), pp. 168-176 | ||
| 504 | |a Efsen, A.M., Schultze, A., Post, F.A., Panteleev, A., Furrer, H., Miller, R.F., Major challenges in clinical management of TB/HIV coinfected patients in Eastern Europe compared with Western Europe and Latin America (2015) PLoS ONE, 10 (12). , e0145380 | ||
| 504 | |a Mocroft, A., Lundgren, J., Antinori, A., Monforte, A., Brannstrom, J., Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013 (2015) Euro Surveill, 20 (47) | ||
| 504 | |a Post, F.A., Grint, D., Werlinrud, A.M., Panteleev, A., Riekstina, V., Malashenkov, E.A., Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe (2014) J Infect, 68 (3), pp. 259-263 | ||
| 504 | |a Podlekareva, D.N., Efsen, A.M., Schultze, A., Post, F.A., Skrahina, A.M., Panteleev, A., Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study (2016) Lancet HIV, 3 (3), pp. e120-31 | ||
| 504 | |a World Health Organization, Guidelines for the programmatic management of drug-resistant tuberculosis (2011), http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583_eng.pdf, update; Available from: (Accessed 1 October 2017); Gunther, G., Gomez, G.B., Lange, C., Rupert, S., van Leth, F., Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey (2015) Eur Respir J, 45 (4), pp. 1081-1088 | ||
| 504 | |a Lange, C., Abubakar, I., Alffenaar, J.W., Bothamley, G., Caminero, J.A., Carvalho, A.C., Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement (2014) Eur Respir J, 44 (1), pp. 23-63 | ||
| 504 | |a World Health Organization, WHO treatment guidelines for drug-resistant tuberculosis (2016), http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf, update; Available from: (Accessed 1 October 2017); Conradie, F., Diacon, A., Everitt, D., Mendel, C., Niekerk, C., Howell, P., The NIX-TB Trial Of Pretomanid, Bedaquiline And Linezolid To TreaT XDR-TB (2017), Abstract number 80LB. Oral presentation from Conference on Retroviruses and Opportunistic Infections (CROI); Ahuja, S.D., Ashkin, D., Avendano, M., Banerjee, R., Bauer, M., Bayona, J.N., Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients (2012) PLoS Med, 9 (8), p. e1001300 | ||
| 504 | |a Abubakar, I., Zignol, M., Falzon, D., Raviglione, M., Ditiu, L., Masham, S., Drug-resistant tuberculosis: time for visionary political leadership (2013) Lancet Infect Dis, 13 (6), pp. 529-539 | ||
| 504 | |a Strobe Group, Strobe statement (2009), http://strobe-statement.org/index.php?id=strobe-home, Available from: (Accessed 1 October 2017); World Health Organization, Treatment of tuberculosis guidelines fourth edition (2010), http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1, Available from: (Accessed 1 October 2017); Xie, Y.L., Chakravorty, S., Armstrong, D.T., Hall, S.L., Via, L.E., Song, T., Evaluation of a rapid molecular drug-susceptibility test for tuberculosis (2017) N Engl J Med, 377 (11), pp. 1043-1054 | ||
| 504 | |a Zignol, M., Dean, A.S., Alikhanova, N., Andres, S., Cabibbe, A.M., Cirillo, D.M., Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project (2016) Lancet Infect Dis, 16 (10), pp. 1185-1192 | ||
| 504 | |a Gunther, G., van Leth, F., Altet, N., Dedicoat, M., Duarte, R., Gualano, G., Beyond multidrug-resistant tuberculosis in Europe: a TBNET study (2015) Int J Tuberc Lung Dis, 19 (12), pp. 1524-1527 | ||
| 504 | |a Podlekareva, D.N.S.A., Panteleev, A., Skrahina, A.M., Miro, J.M., Rakhmanova, A., Furrer, H., One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America (2016), and the; TB:HIV study in EuroCoord#; Accepted for publication in AIDS; Ahmad Khan, F., Gelmanova, I.Y., Franke, M.F., Atwood, S., Zemlyanaya, N.A., Unakova, I.A., Aggressive regimens reduce risk of recurrence after successful treatment of MDR-TB (2016) Clin Infect Dis, 63, pp. 214-220 | ||
| 504 | |a Franke, M.F., Appleton, S.C., Mitnick, C.D., Furin, J.J., Bayona, J., Chalco, K., Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence (2013) Clin Infect Dis, 56 (6), pp. 770-776 | ||
| 504 | |a Velasquez, G.E., Becerra, M.C., Gelmanova, I.Y., Pasechnikov, A.D., Yedilbayev, A., Shin, S.S., Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death (2014) Clin Infect Dis, 59 (1), pp. 9-15 | ||
| 504 | |a Mansfeld, M., Skrahina, A., Shepherd, L., Schultze, A., Panteleev, A.M., Miller, R.F., Major differences in organization and availability of health care and medicines for HIV/TB coinfected patients across Europe (2015) HIV Med, 16 (9), pp. 544-552 | ||
| 504 | |a Abdool Karim, S.S., Naidoo, K., Grobler, A., Padayatchi, N., Baxter, C., Gray, A., Timing of initiation of antiretroviral drugs during tuberculosis therapy (2010) N Engl J Med, 362 (8), pp. 697-706 | ||
| 504 | |a Blanc, F.X., Sok, T., Laureillard, D., Borand, L., Rekacewicz, C., Nerrienet, E., Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis (2011) N Engl J Med, 365 (16), pp. 1471-1481 | ||
| 504 | |a Group, I.S.S., Lundgren, J.D., Babiker, A.G., Gordin, F., Emery, S., Grund, B., Initiation of antiretroviral therapy in early asymptomatic HIV infection (2015) N Engl J Med, 373 (9), pp. 795-807 | ||
| 504 | |a Havlir, D.V., Kendall, M.A., Ive, P., Kumwenda, J., Swindells, S., Qasba, S.S., Timing of antiretroviral therapy for HIV-1 infection and tuberculosis (2011) N Engl J Med, 365 (16), pp. 1482-1491 | ||
| 504 | |a UNAIDS, 90-90-90 An ambitious treatment target to help end the AIDS epidemic (2014), http://www.unaids.org/en/resources/documents/2017/90-90-90, Available from: (Accessed 1 October 2017); Satti, H., McLaughlin, M.M., Hedt-Gauthier, B., Atwood, S.S., Omotayo, D.B., Ntlamelle, L., Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho (2012) PLoS ONE, 7 (10). , e46943 | ||
| 504 | |a Shin, S.S., Modongo, C., Boyd, R., Caiphus, C., Kuate, L., Kgwaadira, B., High treatment success rates among HIV-infected multidrug-resistant tuberculosis patients after expansion of antiretroviral therapy in Botswana, 2006–2013 (2017) J Acquir Immune Defic Syndr, 74, pp. 65-71 | ||
| 504 | |a Umanah, T., Ncayiyana, J., Padanilam, X., Nyasulu, P.S., Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa (2015) BMC Infect Dis, 15, p. 478 | ||
| 504 | |a Isaakidis, P., Casas, E.C., Das, M., Tseretopoulou, X., Ntzani, E.E., Ford, N., Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis (2015) Int J Tuberc Lung Dis, 19 (8), pp. 969-978 | ||
| 504 | |a Podlekareva, D.N., Panteleev, A.M., Grint, D., Post, F.A., Miro, J.M., Bruyand, M., Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe (2014) Eur Respir J, 43 (1), pp. 166-177 | ||
| 504 | |a Morozova, O., Dvoryak, S., Altice, F.L., Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine (2013) Int J Drug Policy, 24 (6), pp. e91-8 | ||
| 520 | 3 | |a Objectives Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB and HIV management remain scarce. Methods In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant (MDR) TB and use of antiretroviral therapy (ART). Results A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug resistance) and 130 pan-susceptible TB. Adequate initial TB treatment was provided for 8% of patients with MDR-TB compared with 80% of those with pan-susceptible TB. By twelve months, an estimated 57.3% (95%CI 41.5–74.1) of MDR-TB patients had started adequate treatment. While 67% received ART, HIV-RNA suppression was demonstrated in only 23%. Conclusions Our results show that internationally recommended MDR-TB treatment regimens were infrequently used and that ART use and viral suppression was well below the target of 90%, reflecting the challenging patient population and the environment in which health care is provided. Urgent improvement of management of patients with TB/HIV in EE, in particular for those with MDR-TB, is needed and includes widespread access to rapid TB diagnostics, better access to and use of second-line TB drugs, timely ART initiation with viral load monitoring, and integration of TB/HIV care. © 2017 The British Infection Association |l eng | |
| 536 | |a Detalles de la financiación: 260694 | ||
| 536 | |a Detalles de la financiación: 666 | ||
| 536 | |a Detalles de la financiación: Ministerio de Economía y Competitividad | ||
| 536 | |a Detalles de la financiación: Swiss Transplant Cohort Study | ||
| 536 | |a Detalles de la financiación: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, # 148522 | ||
| 536 | |a Detalles de la financiación: Instituto de Salud Carlos III | ||
| 536 | |a Detalles de la financiación: 15/00168 | ||
| 536 | |a Detalles de la financiación: Funding: This work was supported by EU – 7th Framework ( FP7/2007-2013 , EuroCoord n 260694) programme. The funding source had no role in study design, the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. | ||
| 536 | |a Detalles de la financiación: The TB:HIV study group Eastern Europe Belarus: Belarusian State Medical University, Department of Infectious Disease: I. Karpov (PI), A. Vassilenko; Republican Research and Practical Centre for Pulmonology and TB (Minsk): A. Skrahina (PI), D. Klimuk, A. Skrahin, O. Kondratenko and A. Zalutskaya; Gomel State Medical University (Gomel): V. Bondarenko (PI), V. Mitsura, E. Kozorez, O. Tumash; Gomel Region Centre for Hygiene: O. Suetnov (PI) and D. Paduto. Estonia: East Viru Central Hospital (Kohtla-Jarve): V. Iljina (PI) and T. Kummik. Georgia: Infectious Diseases, AIDS and Clinical Immunology Research Center (Tiblisi): N. Bolokadze (PI), K. Mshvidobadze and N. Lanchava; National Center for Tuberculosis and Lung Diseases of Georgia (Tibilisi): L. Goginashvili, L. Mikiashvili and N. Bablishvili. Latvia: Infectology Centre of Latvia (Riga): B. Rozentale (PI), I. Zeltina and I. Janushkevich. Lithuania: Centre for Communicable Diseases and AIDS (Vilnius): I. Caplinskiene (PI), S. Caplinskas, Z. Kancauskiene. Poland: Wojewodski Szpital Zakanzy/Medical University of Warsaw (Warszawa): R. Podlasin (PI), A. Wiercinska-Drapalo (PI), M. Thompson and J. Kozlowska; Wojewodski Szpital Specjalistyczny/Medical University Teaching Hospital (Bialystok): A. Grezesczuk (PI); Jozef Strus Multidisciplinary City Hospital (Poznan): M. Bura (PI); Wroclaw University School of Medicine (Wroclaw): B. Knysz (PI) and M. Inglot; Jagiellonian University Medical College (Krakow): A. Garlicki (PI) and J. Loster. Romania: Dr. Victor Babes Hospital (Bucharest): S. Tetradov (PI) and D. Duiculescu (†). Russia: Botkin Hospital of Infectious Diseases (St. Petersburg): A. Rakhmanova (PI†), O. Panteleeva, A. Yakovlev, A. Kozlov, A. Tyukalova and Y. Vlasova; City TB Hospital No. 2 (St. Petersburg): A. Panteleev (PI); Center for Prevention and Control of AIDS (Veliky, Novgorod): T. Trofimov (PI); Medical University Povoljskiy Federal Region. Ukraine: Crimean Republican AIDS Centre (Simferopol): G. Kyselyova (PI). Western Europe Denmark: Rigshospitalet (Cph): AB. Andersen (PI); Hvidovre University Hospital: K. Thorsteinsson. Belgium: CHU Saint-Pierre (Brussels): MC Payen (PI), K. Kabeya and C. Necsoi. France: Aquitaine Cohort. Cohort administration: F. Dabis (PI) and M. Bruyand. Participating Centers and Physicians: Bordeaux University Hospital: P. Morlat; Arcachon Hospital: A. Dupont; Dax Hospital: Y. Gerard; Bayonne Hospital: F. Bonnal; Libourne Hospital: J. Ceccaldi; Mont-de-Marsan Hospital: S. De Witte; Pau Hospital: E. Monlun; Périgueux Hospital: P. Lataste; Villeneuve-sur-Lot Hospital: I. Chossat. Switzerland, Swiss HIV Cohort Study (SHCS, www.shcs.ch ): Cohorte administration: M. Sagette and M. Rickenbach. Participating Centers and Physicians: University Hospital Basel: L. Elzi and M. Battegay; University Hospital Bern: H. Furrer (PI); Hopital Cantonal Universitaire, Geneve: D. Sculier and A. Calmy; Centre Hospitalaire Universitaire Vaudois, Lausanne: M. Cavassini; Hospital of Lugano: A. Bruno and E. Bernasconi; Cantonal Hospital St. Gallen: M. Hoffmann and P. Vernazza; University Hospital Zurich: J. Fehr and Prof. R. Weber. This study has been co-financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (grant # 148522) and by SHCS project 666. The data are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals, 15 affiliated hospitals and 36 private physicians).The members of the Swiss HIV Cohort Study are: Aubert V, Battegay M, Bernasconi E, Böni J, Bucher HC, Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the Clinical and Laboratory Committee), Fux CA, Gorgievski M, Günthard H (President of the SHCS), Haerry D (deputy of “Positive Council”), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A (Chairman of the Scientific Board), Regenass S, Rickenbach M (Head of Data Center), Rudin C (Chairman of the Mother & Child Substudy), Schöni-Affolter F, Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S. United Kingdom: Mortimer Market Centre (London): R. Miller (PI) and N. Vora; St. Mary's Hospital: G. Cooke (PI) and S. Mullaney; North Manchester General Hospital: E. Wilkins (PI) and V. George; Sheffield Teaching Hospitals: P. Collini (PI) and D. Dockrell; King's College Hospital (London): F. Post (PI), L. Campbell, R. Brum, E. Mabonga and P. Saigal. Queen Elizabeth Hospital: S. Kegg (PI); North Middlesex University Hospital: J. Ainsworth (PI) and A. Waters. Leicester Royal Infirmary: J. Dhar (PI) and L. Mashonganyika. Southern Europe: Italy: IRCCS – Ospedale L. Spallanzani (Rome): E. Girardi (PI), A Rianda, V. Galati, C. Pinnetti and C. Tommasi; AO San Gerardo (Monza): G. Lapadula (PI); IRCCS AOU San Martino – IST di Genoa (Genova): A. Di Biagio (PI) and A. Parisini; Clinic of Infectious Diseases, University of Bari (Bari): S. Carbonara (PI), G. Angarano and M. Purgatorio; University of Brescia Spedali Civili: A. Matteelli (PI) and A. Apostoli. Spain: Barcelona Cohort funded by the Spanish HIV/AIDS Research Network. Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Madrid (Spain) provided JMM a personal intensification research grant #INT15/00168 during 2016.: Hospital Clinic of Barcelona: J.M. Miro (PI), C. Manzardo, C. Ligero and J. Gonzalez; Hospital del Mar: F. Sanchez, H. Knobel, M. Salvadó and J.L. Lopez-Colomes; Mutua de Terrassa: X. Martínez-Lacasa and E. Cuchí; Hospital Universitari Vall d'Hebrón: V. Falcó, A. Curran, M.T. Tortola, I. Ocaña and R. Vidal; Hospital Universitari de la Santa Creu i Sant Pau: MA. Sambeat, V. Pomar and P. Coll; Hospital Universitari de Bellvitge: D. Pozamczer, M. Saumoy and F. Alcaide; Agencia de Salud Pública de Barcelona: J. Caylà, A. Moreno, J.P. Millet, A. Orcau, L. Fina, L. del Baño, L.L. Roldan. Hospital Universitario Donostia (San Sebastian): JA. Iribarren (PI) and M. Ibarguren; Hospital Universitario Ramon y Cajal (Madrid): S. Moreno (PI) and A. González; Hospital Universitario ‘Gregorio Maranon’ (Madrid): P. Miralles (PI) and T. Aldámiz-Echevarría. Latin America The CICAL Cohort: Cohorte administration: M. Losso (PI), J. Toibaro and L. Gambardella. Participating Centers and Physicians: Argentina: Hospital J. M. Ramos Mejía (Buenos Aires): J. Toibaro and L. Moreno Macias; Hospital Paroissien (BA): E. Warley (PI) and S. Tavella; Hospital Piñero (BA): O. Garcia Messina and O. Gear; Hospital Nacional Profesor Alejandro Posadas: H. Laplume; Hospital Rawson (Cordoba): C. Marson (PI); Hospital San Juan de Dios (La Plata): J. Contarelia and M. Michaan; Hospital General de Agudos Donación F. Santojani: P. Scapellato and D. D Alessandro; Hospital Francisco Javier Muñiz (BA): B. Bartoletti and D. Palmero; Hospital Jujuy: C. Elias. Chile: Fundación Arriaran (Santiago): C. Cortes. México: INNcMZS (México DF): B. Crabtree (PI); Hospital General Regional de Leon- CAPACITS: JL Mosqueda Gomez; Hospital Civil de Guadalajara: A. Villanueva and LA Gonzalez Hernandez. TB:HIV steering committee H. Furrer, E. Girardi, J. A. Caylá, M. H. Losso, J. D. Lundgren, A. Panteleev (co-chair), R. Miller, J.M. Miro, Å. B. Andersen, S. Tetradov, F. A. Post (co-chair), A. Skrahin and J. Toibaro. Statistical centre A. Schultze, A. Mocroft. Coordinating centre AM. W. Efsen, M. Mansfeld, B. Aagaard, B. R. Nielsen, A H. Fisher, E.V. Hansen, D. Raben, D. N. Podlekareva, O. Kirk. Appendix | ||
| 593 | |a Belarusian State Medical University, Department of Infectious Disease, Belarus | ||
| 593 | |a Republican Research and Practical Centre for Pulmonology and TB, Minsk, Belarus | ||
| 593 | |a Gomel State Medical University, Gomel, Belarus | ||
| 593 | |a Gomel Region Centre for Hygiene, Belarus | ||
| 593 | |a East Viru Central Hospital, Kohtla-Jarve, Estonia | ||
| 593 | |a Infectious Diseases, AIDS and Clinical Immunology Research Center, Tiblisi, Georgia | ||
| 593 | |a National Center for Tuberculosis and Lung Diseases of Georgia, Tibilisi, Georgia | ||
| 593 | |a Infectology Centre of Latvia, Riga, Latvia | ||
| 593 | |a Centre for Communicable Diseases and AIDS, Vilnius, Lithuania | ||
| 593 | |a Wojewodski Szpital Zakanzy/Medical University of Warsaw, Warszawa, Poland | ||
| 593 | |a Wojewodski Szpital Specjalistyczny/Medical University Teaching Hospital, Bialystok, Poland | ||
| 593 | |a Jozef Strus Multidisciplinary City Hospital, Poznan, Poland | ||
| 593 | |a Wroclaw University School of Medicine, Wroclaw, Poland | ||
| 593 | |a Jagiellonian University Medical College, Krakow, Poland | ||
| 593 | |a Dr. Victor Babes Hospital, Bucharest, Romania | ||
| 593 | |a Botkin Hospital of Infectious Diseases, St. Petersburg, Russian Federation | ||
| 593 | |a City TB Hospital No. 2, St. Petersburg, Russian Federation | ||
| 593 | |a Center for Prevention and Control of AIDS, Veliky Novgorod, Russian Federation | ||
| 593 | |a Crimean Republican AIDS Centre, Simferopol, Ukraine | ||
| 593 | |a Rigshospitalet, Copenhagen, Denmark | ||
| 593 | |a Hvidovre University Hospital, Denmark | ||
| 593 | |a CHU Saint-Pierre, Brussels, Belgium | ||
| 593 | |a Aquitaine Cohort, Cohort Administration, France | ||
| 593 | |a Bordeaux University Hospital, France | ||
| 593 | |a Arcachon Hospital, France | ||
| 593 | |a Dax Hospital, France | ||
| 593 | |a Bayonne Hospital, France | ||
| 593 | |a Libourne Hospital, France | ||
| 593 | |a Mont-de-Marsan Hospital, France | ||
| 593 | |a Pau Hospital, France | ||
| 593 | |a Périgueux Hospital, France | ||
| 593 | |a Villeneuve-sur-Lot Hospital, France | ||
| 593 | |a Mortimer Market Centre, London, United Kingdom | ||
| 593 | |a St. Mary's Hospital, United Kingdom | ||
| 593 | |a North Manchester General Hospital, United Kingdom | ||
| 593 | |a Sheffield Teaching Hospitals, United Kingdom | ||
| 593 | |a King's College Hospital, London, United Kingdom | ||
| 593 | |a Queen Elizabeth Hospital, United Kingdom | ||
| 593 | |a North Middlesex University Hospital, United Kingdom | ||
| 593 | |a Leicester Royal Infirmary, United Kingdom | ||
| 593 | |a IRCCS– Ospedale L. Spallanzani, Rome, Italy | ||
| 593 | |a AO San Gerardo, Monza, Italy | ||
| 593 | |a IRCCS AOU San Martino – IST di Genoa, Genova, Italy | ||
| 593 | |a Clinic of Infectious Diseases, University of Bari, Bari, Italy | ||
| 593 | |a University of Brescia Spedali Civili, Italy | ||
| 593 | |a Hospital J. M. Ramos Mejía, Buenos Aires, Argentina | ||
| 593 | |a Hospital Paroissien, Buenos Aires, Argentina | ||
| 593 | |a Hospital Piñero, Buenos Aires, Argentina | ||
| 593 | |a Hospital Nacional Profesor Alejandro Posadas, Argentina | ||
| 593 | |a Hospital Rawson, Cordoba, Argentina | ||
| 593 | |a Hospital San Juan de Dios, La Plata, Argentina | ||
| 593 | |a Hospital General de Agudos Donación F. Santojani, Argentina | ||
| 593 | |a Hospital Francisco Javier Muñiz, Buenos Aires, Argentina | ||
| 593 | |a Hospital Jujuy, Argentina | ||
| 593 | |a Fundación Arriaran, Santiago, Chile | ||
| 593 | |a INNcMZS, México DF, Mexico | ||
| 593 | |a Hospital General Regional de Leon- CAPACITS, Mexico | ||
| 593 | |a Hospital Civil de Guadalajara, Mexico | ||
| 593 | |a CHIP, Department of Infectious Diseases, Finsencentret, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, 2100, Denmark | ||
| 593 | |a Department of Infection and Population Health, University College London Medical School, Rowland Hill Street, London, NW3 2PF, United Kingdom | ||
| 593 | |a Centre for Sexual Health and HIV Research, Mortimer Market Centre, University College London, London, WC1E 6JB, United Kingdom | ||
| 593 | |a Department of HIV/TB, TB hospital 2, Ushinskogo str 39/1 – 122, St. Petersburg, 195267, Russian Federation | ||
| 593 | |a Clinical Department, Republican Research and Practical Centre for Pulmonology and TB, Minsk, Belarus | ||
| 593 | |a Infectious Diseases Service, Hospital Clinic – IDIBAPS, University of Barcelona, Villarroel, 170, Barcelona, 08036, Spain | ||
| 593 | |a Department of Infectious Diseases INMI “L. Spallanzani”, Ospedale L Spallanzani, Via Portuense, 292, Rome, 00149, Italy | ||
| 593 | |a Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, CH-3010, Switzerland | ||
| 593 | |a Department of immunocompromised, Hospital J.M. Ramos Mejia, Pabellón de Cliníca, 2do Piso, Buenos Aires, CP 1221, Argentina | ||
| 593 | |a Agencia de Salud Pública de Barcelona, Barcelona, Spain | ||
| 593 | |a Programa Integrado de Investigación en Tuberculosis de SEPAR (PII-TB), Barcelona, Spain | ||
| 593 | |a Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain | ||
| 593 | |a Department of Sexual Health, Caldecot Centre, King's College Hospital, Bessemer Road, London, SE5 9RS, United Kingdom | ||
| 690 | 1 | 0 | |a EASTERN EUROPE |
| 690 | 1 | 0 | |a HIV |
| 690 | 1 | 0 | |a MDR-TB |
| 690 | 1 | 0 | |a AMINOSALICYLIC ACID |
| 690 | 1 | 0 | |a CYCLOSERINE |
| 690 | 1 | 0 | |a ETHAMBUTOL |
| 690 | 1 | 0 | |a ETHIONAMIDE |
| 690 | 1 | 0 | |a ISONIAZID |
| 690 | 1 | 0 | |a PROTIONAMIDE |
| 690 | 1 | 0 | |a PYRAZINAMIDE |
| 690 | 1 | 0 | |a QUINOLINE DERIVED ANTIINFECTIVE AGENT |
| 690 | 1 | 0 | |a RIFAMPICIN |
| 690 | 1 | 0 | |a STREPTOMYCIN |
| 690 | 1 | 0 | |a TERIZIDONE |
| 690 | 1 | 0 | |a ADULT |
| 690 | 1 | 0 | |a ANTIRETROVIRAL THERAPY |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a COHORT ANALYSIS |
| 690 | 1 | 0 | |a DRUG EFFICACY |
| 690 | 1 | 0 | |a EASTERN EUROPE |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a FOLLOW UP |
| 690 | 1 | 0 | |a HUMAN |
| 690 | 1 | 0 | |a HUMAN IMMUNODEFICIENCY VIRUS INFECTION |
| 690 | 1 | 0 | |a INFECTION SENSITIVITY |
| 690 | 1 | 0 | |a MAJOR CLINICAL STUDY |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a MIXED INFECTION |
| 690 | 1 | 0 | |a MULTIDRUG RESISTANT TUBERCULOSIS |
| 690 | 1 | 0 | |a PATIENT CARE |
| 690 | 1 | 0 | |a PATIENT MONITORING |
| 690 | 1 | 0 | |a PROSPECTIVE STUDY |
| 690 | 1 | 0 | |a TREATMENT OUTCOME |
| 690 | 1 | 0 | |a VIRUS LOAD |
| 650 | 1 | 7 | |2 spines |a TUBERCULOSIS |
| 650 | 1 | 7 | |2 spines |a VIRUS RNA |
| 773 | 0 | |d W.B. Saunders Ltd, 2018 |g v. 76 |h pp. 44-54 |k n. 1 |p J. Infect. |x 01634453 |t Journal of Infection | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-85032918910&doi=10.1016%2fj.jinf.2017.10.007&partnerID=40&md5=c7e55aebd915d8d9fb99842702c211c5 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jinf.2017.10.007 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_01634453_v76_n1_p44_Efsen |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_01634453_v76_n1_p44_Efsen |y Registro en la Biblioteca Digital |
| 961 | |a paper_01634453_v76_n1_p44_Efsen |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 86338 | ||